Physician profile
William D Buck
NPI 1023060902
$5,626.29
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $628 · 2021: $803 · 2022: $1,310 · 2023: $1,152 · 2024: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $944.37 | 2019-2024 | |
| Amgen INC. | $779.52 | 2019-2024 | Otezla, Repatha, Tavneos |
| Lilly USA, LLC | $540.25 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $522.59 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $387.77 | 2021-2024 | Vraylar, Ubrelvy, Synthroid |
| Janssen Pharmaceuticals, INC | $264.57 | 2019-2022 | |
| Astellas Pharma US INC | $261.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $255.97 | 2019-2024 | Fasenra, Breztri, Lokelma |
| Novartis Pharmaceuticals Corporation | $211.41 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.47 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $138.18 | 2019-2023 | Jynarque |
| Genzyme Corporation | $133.21 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $105.87 | 2019-2023 | |
| Glaxosmithkline, LLC. | $103.58 | 2020-2024 | Pediarix, Rotarix, Bexsero |
| Merck Sharp & Dohme LLC | $81.49 | 2019-2023 | Dificid |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.